Strides Pharma Science Ltd (STAR) Q1FY27 Concall Summary - Jun-2026 Qtr
Performance Overview
- The company reported a steady start to FY27, achieving a 13% year-on-year growth in top line, demonstrating resilience despite a volatile geopolitical environment and ongoing supply chain disruptions.
- The ex-US business was a significant growth driver, recording a strong 17% year-on-year growth, which validates the company's strategy of diversifying its business model beyond the US market.
- Profitability remained stable, with EBITDA margins maintained at 18.2%, broadly in line with the previous quarter, successfully mitigating 13.1 crores in additional operating and freight costs arising from geopolitical issues.
- The US business delivered a stable performance, with a strategic focus on profitability and portfolio quality over aggressive, low-margin growth, while making progress on key growth platforms like controlled substances and nasal sprays.
- The company strengthened its financial position by reducing net debt by 12 crores during the quarter, leading to an improved net debt to EBITDA ratio of 1.52x and an upgraded long-term bank facilities rating to 'CARE A+ Stable'.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.